Disruptive Tech
SCN’s Top Systems Integrators 2022 has published its latest edition. The ProAV industry had to rapidly adjust throughout the covid-19 pandemic and for some, it’s starting to pay off. In Systems Contractor News’ recently published Top 50 list, a new company took the top as a reshuffling occurred across the menu. Some brands posted strong…
Latest
Disruptive Tech
How One Company Innovated to Keep Healthcare Workers Safe
When the COVID-19 pandemic reached the United States, one of the first warning signs that medical facilities weren’t prepared for the effects of the virus was the lack of personal protective equipment available to frontline healthcare workers. Manufacturers have risen to meet this challenge and innovated beyond what we had seen before. One manufacturer, Bullard,…
Disruptive Tech
How North Dakota is Emerging as a UAV Force
When it comes to the world of drones, it is often the smaller states that are making the largest waves. North Dakota has established itself as a top tier market for the research of UAV technology. For UAV research to be useful across the board, the technology needs wide open spaces and lawmakers willing to…
Latest
Analyzing the Suppressive TME in In Vitro Based Assays
In the rapidly advancing field of cancer immunotherapy, accurately modeling the tumor microenvironment (TME) has become essential to improving the predictive power of preclinical drug testing. As immune-modulating therapies surge forward, with over 4,000 immune modulators in development globally, scientists are refining assay technologies that maintain the complexity of patient-specific tumor biology. In vitro platforms…
Targeting T Cells Within the Cancer Immunity Cycle
As cancer immunotherapy continues to reshape treatment landscapes, fine-tuning T-cell responses has become a critical frontier. Recent advances in 3D organoid models and high-content imaging are enabling scientists to closely mimic patient-specific tumor environments—unlocking insights into how T cells behave, respond, and falter under immune checkpoint blockade. With over 4,000 immune modulators in clinical…
Advanced In Vitro Technologies to Investigate Therapeutic Impact on the Cancer Immunity Cycle
As immunotherapy revolutionizes cancer treatment, the need for physiologically relevant preclinical models becomes more urgent than ever. Despite the success of immune checkpoint inhibitors, a large majority of patients fail to achieve long-lasting responses, prompting researchers to explore more complex and predictive assays. The cancer immunity cycle, first described in 2013, remains a central framework…
Inside Oncology Drug Development: Overcoming Resistance with Science
In the last two decades, oncology has undergone a transformation with over 300 new cancer therapies approved by the FDA—many offering novel mechanisms of action. Despite these innovations, resistance to treatment remains a critical challenge, with cancer cells evolving or adapting to evade even the most advanced therapeutics. This issue is particularly pressing given that…